Effect of 577 nm Laser Photocoagulation Combined with Leizumab on Visual Acuity Recovery in Diabetic Retinopathy with Macular Edema
Objective To analyze the effect of 577 nm laser photocoagulation combined with leizumab on patients with diabetic retinopathy (DR) and macular edema (ME).Methods A total of 110 patients with DR and ME admitted to the hospital from May 2021 to July 2023 were selected as the research objects.According to the random number table method, they were divided into a control group and an observation group, with 55 cases in each group.The control group was treated with 577 nm laser photocoagulation, and the observation group was treated with leizumab on this basis.The therapeutic effects of the two groups were compared.Results The total effective rate in the observation group was 94.55％, which was higher than 81.82％in the control group, the absorption time of fundus hemorrhage was (2.59±0.47)weeks, the improvement time of macular edema was (4.25±0.69)weeks, and the absorption time of exudation was (10.54±1.25)weeks, which were shorter than (3.15±0.63)weeks, (5.58±0.71)weeks and (12.21±1.77)weeks in the control group, the incidence of complications was 5.45％in the observation group, which was lower than 20.00％in the control group, the improvement of visual acuity was better than that in the control group, and the differences between the two groups were statistically significant (P<0.05).After treatment, the macular retinal thickness of the observation group was (240.51±19.70)μm, and the central macular thickness was (243.45± 20.36)μm, which were thinner than (282.64±22.29)μm, (350.31±26.49)μm of the control group, the differences between the two groups were statistically significant (P<0.05).Conclusion 577 nm laser photocoagulation combined with leizumab can alleviate symptoms of patients with ME and DR, improve eyesight, macular thickness reduction, and less complications.
NETL
NSTL
万方数据
